Stock Price Quote

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE8127.20-391.35 (-4.59 %)
PREV CLOSE ( ) 8518.55
OPEN PRICE ( ) 8564.95
BID PRICE (QTY) 8124.70 (1)
OFFER PRICE (QTY) 8143.35 (3)
VOLUME 2198
TODAY'S LOW / HIGH ( )8100.00 8564.95
52 WK LOW / HIGH ( )5000 9049.95
NSE8110.80-381.85 (-4.5 %)
PREV CLOSE( ) 8492.65
OPEN PRICE ( ) 8452.65
BID PRICE (QTY) 8102.55 (3)
OFFER PRICE (QTY) 8111.60 (4)
VOLUME 30560
TODAY'S LOW / HIGH( ) 8100.00 8518.00
52 WK LOW / HIGH ( )4800.15 9059.05
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-07 1979
Management Info
Shilpa Divekar Nirula - Chairman Sanjeev Kumar Panchal - Managing Director
Registered Office

Address Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone 080 6774 8000

Email comp.secy@astrazeneca.com

Website www.astrazenecaindia.com/india

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE

NEWS

28Mar AstraZeneca Pharma India informs about
AstraZeneca Pharma India has informed that the company will be discontin..
06Mar AstraZeneca Pharma India gets nod to i
AstraZeneca Pharma India has received permission from the Central Drugs..
04Mar AstraZeneca Pharma India gets CDSCO’s
AstraZeneca Pharma India has received approval from drug regulator - Cen..
04Mar AstraZeneca Pharma India surges on get
Astrazeneca Pharma India is currently trading at Rs. 7050.00, up by 210...
25Feb AstraZeneca Pharma India informs about
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit308.51615.09
Gross Profit 420.2 2195.37
Operating Profit 849.72192.52
Net Sales 4402.912955.28

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Hester Biosciences (BSE)
peergroup  1789.25 (20.00%)
M.Cap ( in Cr)1497.21
Procter&Gamble Healt (BSE)
peergroup  5254.50 (1.98%)
M.Cap ( in Cr)8742.31
Divi's Lab (BSE)
peergroup  5648.45 (1.80%)
M.Cap ( in Cr)150407.86
RPG Life Sciences (BSE)
peergroup  2336.00 (3.55%)
M.Cap ( in Cr)3857.81
Sanofi India (BSE)
peergroup  5910.50 (1.23%)
M.Cap ( in Cr)13589.79

Shareholding Pattern

PROMOTERS 75%
MUTUAL FUNDS/UTI 5.04%
NON-INSTITUTION 16.87%
FI/BANKS/INSURANCE 0.13%
GOVERNMENT 0%
FII 0%

About Astrazeneca Pharma India Ltd.

Astrazeneca Pharma India Ltd. was incorporated in the year 1979. Its today's share price is 8127.2. Its current market capitalisation stands at Rs 20280 Cr. In the latest quarter, company has reported Gross Sales of Rs. 13021.4 Cr and Total Income of Rs.13303.3 Cr. The company's management includes Sandeep Arora, Jesus Javier Diaz Ropero Esteso, Amita Bhave, Monica Widhani, Manasa R, Bhavana Agrawal, Sanjeev Kumar Panchal, Hooi-Bien Chuah, Sylvia Lorena Varela Ramon, Shilpa Divekar Nirula, Revathy Ashok.

It is listed on the BSE with a BSE Code of 506820 , NSE with an NSE Symbol of ASTRAZEN and ISIN of INE203A01020. It's Registered office is at Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring RoadBengaluru-560045, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AF Ferguson & Co, Bharat S Raut & Co, BSR & Co, BSR & Co LLP, Price Waterhouse & Co, Price Waterhouse & Co Chartered Accountants LLP

1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.
1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.
Close X
OPEN

DEMAT ACCOUNT

AND START YOUR

INVESTMENT

JOURNEY WITH US
(You will receive a Call & SMS from our end)
Popup-Character

Disclaimer: NIRMAL BANG SECURITIES PVT LTD: Investment in Securities market are subject to market risks. Read all the related documents carefully before investing. Please read the Do’s and Don’ts prescribed by the Commodity Exchange before trading. We do not offer PMS Service for the Commodity segment. Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO. The securities quoted are exemplary and are not recommendatory. BSE (Member ID- 498): INB011072759, INF011072759, Exchange Registered Member in CDS; NSE MEMEBR ID- 09391): INB230939139, INF230939139, INE230939139; MSEI Member ID-1067): INB260939138, INF260939138, INE260939139: Single Registration No. INZ000202536, PMS Registration No: INP000002981; Research Analyst Registration No: INH000001766; NSDL/ CDSL: IN-DP-CDSL 37-99; Exchange Member ID: MCX - 56460, NCDEX - 1268, ICEX – 2073. Regd. Office: B-2, 301/302, 3rd Floor, Marathon Innova, Off Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013. Tel: 62738000/01; Fax: 62738010 | *NIRMAL BANG NIVESHALAYA PVT LTD: ARN – 111233, Mutual Fund Distributor. Mutual Fund Investments are subject to market risks. Please read the offer documents carefully before Investing.” Regd. Office: B - 201, Khandelwal House, Poddar Road, Near Poddar Park, Malad (East). Mumbai – 400097. | **NIRMAL BANG INSURANCE BROKING PVT LTD: IRDAI Registration No: 795 and Registration Code For the Insurance Broker: IRDAI/DB889/2021. Insurance is the subject matter of the solicitation. For more details on policy terms, conditions, exclusions, limitations, please refer/read policy brochure carefully before concluding sale.